SELLAS Life Sciences Group, Inc.
11.54USD
+0.1900 (+1.67%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on SLS.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 1.0M | 0.0 | — | — | 0.0 | 53.1M |
| Q1 | 1.0M | 0.0 | — | — | — | — |
| Q2 | 0.0 | 0.0 | — | — | — | — |
| Q3 | 0.0 | 0.0 | — | — | 0.0 | — |
| Q4 | 0.0* | 0.0* | — | — | 0.0 | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -.967 | -.608 | -.500 | -.250 | -.200 | -.100 |
| Q1 | -.477 | -.213 | -.210 | -.070 | -.050 | — |
| Q2 | -.186 | -.141 | -.130 | -.070 | -.050 | — |
| Q3 | -.154 | -.150 | -.100 | -.060 | -.050 | — |
| Q4 | -.213* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -.133* |
| -.110* |
| -.070* |
| -.050 |
| — |
Debt level and coverage